Navigation Links
New consensus reached to help tackle multidrug-resistant and extensively drug-resistant TB
Date:3/23/2014

New consensus statements have been developed to help tackle the growing threat of multidrug-resistant tuberculosis (TB) and extensively drug-resistant tuberculosis (TB).

Published online today (24 March 2014) in the European Respiratory Journal the statements mark the first time that physicians who treat patients with multidrug- and extensively drug-resistant TB have reached a consensus on important areas of patient management where scientific evidence is inconclusive.

The World Health Organization (WHO) estimates that currently 450,000 new cases with MDR-TB occur each year. The majority of affected patients live in the WHO European Region.

As the emergence of these forms of the disease is fairly recent, clinical evidence is lacking and could be for many years to come. To help bridge this gap in knowledge, experts from the European-based TBNET network have provided harmonised answers to the key questions for the prevention, diagnosis, treatment and management of multidrug- and extensively drug-resistant TB.

Although some guidelines are available for the treatment of people with multidrug- and extensively drug-resistant TB, this is the first time that a large group of predominantly clinical experts have joined together to provide a consensus on the management of these conditions in Europe.

The consensus statements also include useful checklists with information on which examinations should be performed during the course of the treatment and what is necessary before discharging a patient from the hospital. The authors suggest that the document can be used as a point of reference for physicians across the continent.

Lead author, Professor Christoph Lange, Head of the Respiratory Infections Assembly at the European Respiratory Society, said: "These consensus statements provide very valuable support for physicians treating patients with these deadly conditions in all parts of Europe. The current management of patients with multidrug- and extensively drug-resistant TB is complex, very costly for healthcare systems and burdensome for those who are affected.

"We have harmonised individual expert opinions on the management of multidrug- and extensively drug-resistant TB in adults and children to ensure that consensus is available where clinical evidence is still lacking. As clinicians we hope to improve the treatment of multidrug- and extensively drug-resistant TB and the life of our patients who suffer from these difficult-to-treat conditions."


'/>"/>

Contact: Lauren Anderson
lauren.anderson@europeanlung.org
0044-114-267-2876
European Lung Foundation
Source:Eurekalert  

Related medicine news :

1. GWU consensus report outlines new approaches for evaluating benefits and risks of obesity drugs
2. CRT consensus set to standardize and improve care for patients worldwide
3. IOM President to speak at Schwartz Center Consensus Meeting Nov. 8
4. JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children
5. Hartford consensus aims to improve survival after mass shootings
6. Consensus statement on pediatric arrhythmias released by ESC and AEPC
7. Groundbreaking Consensus Statement Provides a Road Map for Treating Melanoma Patients with Cancer Immunotherapy
8. ASTRO and SSO issue consensus guideline on margins for breast-conserving surgery with WBI
9. Da Vinci Robotic Surgery Lawsuit News: Ohio Law Firm Investigates Da Vinci Robotic Surgery Complications as Settlement is Reached in Louisiana Da Vinci Robot Lawsuit
10. Cherry Creek Medical Weight Loss Has Reached Their Goal
11. ICREATE Technologies announces the new book Seven Symbiotic Collaborations For Spiritual Cashflow to have reached #19 in the Amazon.com bestseller list today morning
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New consensus reached to help tackle multidrug-resistant and extensively drug-resistant TB
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: